Brief: Gensight Biologics Announces Extension Of Day 120 Clock Stop Of LUMEVOQ

Gensight Biologics SA

15/11/2021 07:47

Nov 15 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS ANNOUNCES EXTENSION OF DAY 120 CLOCK
STOP OF
LUMEVOQ® EMA REGULATORY FILING; MAA REVIEW TO RESUME IN APRIL
2022
    * HAS REACHED AN AGREEMENT WITH THE COMMITTEE FOR ADVANCED
THERAPIES (CAT) OF THE EUROPEAN MEDICINES AGENCY (EMA) TO EXTEND
BY 3 MONTHS THE DAY 120 CLOCK STOP DURING THE REVIEW OF THE
LUMEVOQ® MARKETING AUTHORISATION APPLICATION (MAA)

Source text for Eikon:  ID:nBw5T6X8ca 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))